 - Medications or supplements that are known to be inhibitors of P-glycoprotein P-gp andor strong reversible inhibitors of cytochrome P450 CYP 3A within 5 times the inhibitor half-life if a reasonable half-life estimate is known or within 7 days if a reasonable half-life estimate is unknown before the first dose of study drug. In general, the use of these agents is not permitted during the study. 